Multiple myeloma: practice patterns across Europe
Real-world data describing management of patients with multiple myeloma are limited. A European (Belgium, France, Germany, Italy, Spain, Switzerland, UK) observational chart review was conducted to address this. Physicians completed questionnaires for every patient seen during a 2-4-week observation...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
13 June 2016
|
| In: |
British journal of haematology
Year: 2016, Volume: 175, Issue: 1, Pages: 66-76 |
| ISSN: | 1365-2141 |
| DOI: | 10.1111/bjh.14193 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1111/bjh.14193 Verlag, Volltext: http://onlinelibrary.wiley.com/doi/10.1111/bjh.14193/abstract 
|
| Author Notes: | Marc S. Raab, Michele Cavo, Michel Delforge, Christoph Driessen, Leah Fink, Alain Flinois, Sebastian Gonzalez-McQuire, Reza Safaei, Lionel Karlin, Maria-Victoria Mateos, Paul Schoen, Kwee Yong |
| Summary: | Real-world data describing management of patients with multiple myeloma are limited. A European (Belgium, France, Germany, Italy, Spain, Switzerland, UK) observational chart review was conducted to address this. Physicians completed questionnaires for every patient seen during a 2-4-week observation period, regardless of treatment status. A total of 435 physicians completed 7635 cross-sectional chart reviews. Overall, 47% of patients were undergoing anti-tumour drug treatment, 42% had previously received ≥1 line of treatment and 12% had never received anti-tumour drug treatment. Of the patients treated by oncologists, onco-haematologists or internists, 95% received, or were expected to receive, at least one line of anti-tumour drug treatment, 61% received ≥2 lines of therapy and 38% received ≥3 lines. Except in the UK, the most commonly used induction therapies contained bortezomib (48%); lenalidomide was the most commonly used first-line maintenance therapy (45%) and second- and third-line agent overall (60% and 52% of patients at those lines, respectively). Bortezomib retreatment was used in 47% of patients who received it first line. Treatment patterns became more diverse with subsequent treatment lines. This study provides insight into real-world treatment patterns in Europe. While treatment practices are broadly similar across countries, some notable differences in the agents used exist. |
|---|---|
| Item Description: | Gesehen am 01.12.2017 |
| Physical Description: | Online Resource |
| ISSN: | 1365-2141 |
| DOI: | 10.1111/bjh.14193 |